CBD Gummies Stock

CBDISTILLERY

Buy CBD Oil Online

An in-depth look at the leading CBD stocks in the U.S stock market this year. Here’s what you need to know. CBDS | Complete Cannabis Sativa Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Investing in CBD Stocks

Sometimes the best time to invest in a relatively new market is after the initial euphoria evaporates. That could very well be the case with investing in CBD stocks.

CBD is short for cannabidiol, which is a chemical found in the cannabis plant. CBD doesn’t produce a high but has been found to have therapeutic benefits.

The U.S. legalized hemp-derived CBD at the federal level with the 2018 Farm Bill. The mere anticipation of the passage of this legislation stoked investors’ interest in the stocks of companies involved in the CBD industry.

Although federal legalization served as a key milestone, the U.S. Food and Drug Administration (FDA) still hasn’t finalized regulations for CBD food supplements. As a result, the CBD opportunity in the U.S. hasn’t delivered on investors’ lofty ambitions — at least not yet. However, the pressure is mounting for CBD regulations to be eased. Even the U.S. Congress has gotten involved with bill proposals to change the federal regulation of CBD products.

The CBD market could expand in the not-too-distant future with the finalization of regulations. Now could be a great time for investors to check out CBD stocks. Here are five CBD stocks to consider in 2022.

Data sources: Yahoo! Finance, company press releases. Market caps as of Feb. 21, 2022.

Company Market Cap Overview
Canopy Growth (NASDAQ:CGC) $3 billion Canadian cannabis producer with U.S. CBD operations.
Charlotte’s Web Holdings (OTC:CWBHF) $172 million Leading CBD products company.
Cresco Labs (OTC:CRLBF) $2.1 billion U.S. cannabis operator that markets CBD products.
Jazz Pharmaceuticals (NASDAQ:JAZZ) $8.5 billion Pharmaceutical company with the first FDA-approved CBD drug.
The Valens Company (NASDAQ:VLNCF) $166 million Canadian company that provides extraction services used to produce CBD and cannabis derivative products.

Canopy Growth

For a while, Canopy Growth ranked as the biggest marijuana stock in the world based on market cap. It remains one of the largest companies in the cannabis industry with top-tier positions in the Canadian medical and recreational marijuana markets and the German medical cannabis market.

Canopy Growth can’t enter the U.S. cannabis market and maintain its listing on a major U.S. stock exchange as long as marijuana is illegal at the federal level. However, the company is already a player in the U.S. hemp-derived CBD market.

In 2019, Canopy Growth teamed up with businesswoman and TV celebrity Martha Stewart to develop CBD products for the U.S. market. The company now has a line of CBD brands with Stewart. It also has other CBD products that include Whisl, the No. 1 CBD-only vape in the U.S. market.

Canopy Growth isn’t profitable yet. However, it does have a large cash stockpile, thanks in large part to investments by beverage giant Constellation Brands (NYSE:STZ), the company’s biggest shareholder.

See also  Pfizer CBD Gummies

The CBD opportunity is only a secondary reason to consider this stock. The primary potential catalyst for Canopy Growth is the prospect that U.S. federal cannabis laws will be changed and allow the company to enter the lucrative U.S. cannabis market.

Charlotte’s Web Holdings

If you’re looking for a pure-play CBD stock, Charlotte’s Web could be right up your alley. The company pioneered the hemp CBD industry in 2011, and it still ranks No. 1 based on market share.

Charlotte’s Web markets a wide range of CBD products. From bath and beauty to ingestibles and topicals, the company covers all the bases when it comes to CBD. It even sells CBD products for pets.

The company’s CBD products are available at more than 14,000 retail outlets. About 8,000 healthcare practitioners also distribute Charlotte’s Web’s products, and the company has a strong online presence. More than half of its total revenue stems from direct-to-consumer e-commerce sales.

Charlotte’s Web isn’t resting on its laurels. It plans to launch CBD beverages in the second half of 2022. Market researcher Brightfield Group projects that the CBD beverage market will reach $1.3 billion in 2026, up from $245 million in 2021.

However, Charlotte’s Web’s stock performance over the past couple of years has been disappointing. But the company now has a new CEO with former Bacardi executive Jacques Tortoroli taking the helm in December 2021. The potential for the finalization of regulations regarding CBD dietary supplements could be just what the stock needs to mount a major comeback.

Cresco Labs

Cresco Labs is a U.S.-based cannabis operator that markets recreational and medical cannabis products in 10 states, all of which rank among the 20 most-populated in the U.S. (and with seven in the top 10).

The company isn’t just a cannabis producer and retailer. Cresco also is the No. 1 U.S. wholesaler of branded cannabis products containing CBD, including its Wonder gummies.

Cresco has achieved tremendous success in recent years. The company’s revenue has grown significantly, both organically and through acquisitions. It’s consistently profitable. Cresco’s solid balance sheet should also enable it to continue expanding into new markets.

Probably the biggest knock against Cresco is that the company can’t list its shares on a major U.S. stock exchange as long as marijuana remains illegal at the federal level. However, this limitation also is a key factor behind the stock’s attractive valuation compared to Canadian pot stocks.

Jazz Pharmaceuticals

You might be surprised to find a pharmaceutical stock listed among the top CBD stocks to consider. But Jazz Pharmaceuticals has a direct and important connection with CBD. In 2018, the company’s Epidiolex became the first CBD product made from the cannabis plant to win FDA approval.

Jazz actually didn’t own Epidiolex at that time. It acquired GW Pharmaceuticals, which developed the CBD drug to treat epileptic seizures, for $6.7 billion in 2021 .

See also  Euphoria CBD Oil

Epidiolex is still a long way from generating annual sales of $1 billion or more, as some analysts projected after it was first approved in the U.S. However, sales continue to pick up as the drug launches in additional European countries.

Jazz also has other growth drivers in its lineup. Sleep disorder drug Xywav is gaining momentum. Sales are soaring for another sleep disorder drug, Sunosi, as well as blood cancer drug Rylaze and lung cancer drug Zepzelca.

Related Investing Topics

Investing in Marijuana Stocks

The continued legalization of marijuana means growth for companies in this sector.

Investing in Psychedelic Stocks

It turns out that “magic mushrooms” may have medical applications.

Investing in Biotech Stocks in 2022

These companies create drugs and treatments for some of the biggest medical problems of our time.

Investing in Healthcare Stocks

Healthcare is a universal need. Companies in this broad-based sector can produce healthy returns.

The Valens Company

One of the important steps in investing in marijuana stocks is to understand the different types of companies. Ancillary businesses that support the industry can sometimes have even more attractive prospects than pure plays. The Valens Company is a good example.

Valens is the largest third-party extraction company serving the Canadian cannabis industry. It uses different methods to extract cannabinoids (including CBD) from cannabis. Valens also markets its own cannabis products, which is part of its strategy to transition into a leading cannabis consumer packaged goods company.

The company’s Green Roads already ranks among the top 10 CBD brands in the U.S. Green Roads products are available in about 7,000 retail locations. Valens hopes to also achieve success in Canada if over-the-counter CBD sales are permitted in the country.

Like most Canadian cannabis-related stocks, Valens hasn’t made investors happy over the past year. However, its shares trade at a more attractive valuation than most U.S. and Canadian cannabis stocks.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Constellation Brands, Cresco Labs Inc., and The Valens Company Inc. The Motley Fool recommends Charlotte’s Web and Charlotte’s Web Holdings. The Motley Fool has a disclosure policy.

Cannabis Sativa Inc.

Have Watchlists? Log in to see them here or sign up to get started.

No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Uh oh

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Overview

CBDS Overview

Key Data

Performance

Recent News

    MarketWatch Dow Jones

Cannabis stock Cronos soars 24% as Altria takes major stake, sparking sector rally

Cannabis stocks mixed after Coca-Cola says it has no plans for sector

Marijuana stocks bounce back from long losing streak; Aurora Cannabis’ stock sees first U.S.-listed gains

Aurora Cannabis stock leads sector higher after news it will start trading on NYSE next week

Cannabis stocks rally on continued excitement about CBD-infused drinks

Tilray erases early gains in another day of volatile trade for cannabis stocks

Tilray leads cannabis stocks higher as sector continues to rally

Cannabis stocks rally with Aurora leading, after report that Coca-Cola has held talks on potential investment

Cannabis stocks rallied across the board on Monday, with Aurora Cannabis Inc. leading the charge, after a report that Coca-Cola Co. has been in talks with the company. Coca-Cola declined to comment on Aurora, but confirm.

See also  Thc CBD Oil

Tilray is the sole bright spot among cannabis stocks as sector sells off

Cannabis stocks boosted by Aurora’s acquisition of Uruguay-based ICC Labs

Cannabis rally braked by Tilray downgrade, allowing investors to lock in recent gains

Cannabis stocks rally anew as analysts cheer latest tie-ups in growing sector

Canopy Growth is ‘at the top of the food chain’ as Canada gears up for legal weed

Marijuana stocks slammed for a second straight day

Marijuana-related stocks fell again Friday, extending their prior-session losses after the U.S. Justice Department overturned an Obama-era protection for states that have legalized the plant. The news put the brakes on a s.

Marijuana stocks tank on news Trump administration to rescind state protections from pot prosecutions

Barron’s Sessions Extinguishes Marijuana Rally

Cannabis-related stocks rally as marijuana sales go mainstream in California

Shares of Cannabis Sativa are down nearly 3%

Corrected Canadian pot IPO Bedrocan is high flier

This marijuana stock is 900% higher and still smoking

No Headlines Available

No Headlines Available

No Headlines Available

    Other News Press Releases

MJ Harvest Signs Letter Of Intent To Merge With Cannabis Sativa, Inc.

No Headlines Available

No Headlines Available

No Headlines Available

Cannabis Sativa Inc.

Cannabis Sativa, Inc. operates as a pharmaceutical company. The firm develops, manufactures, and sells herbal based skin care products in the United States and internationally. It offers Recover, a deep penetrating healing balm used to relieve pain for sore muscles, joints, arthritic, and back pain; Trauma Cream, a cream for blended infusion of cannabinoids and THC; Face Garden, an antioxidant moisturizing cream for the face; Body Garden, a moisturizing body lotion; and Lip Garden, an emollient balm. The firm’s brands include Prestocorp, GK Manufacturing, iBudtender, Wild Earth Naturals, Ecuadorian Sativa and CTA, Patented Cannabis Lozenge, hi Brands International, White Rabbit Brand, and Virgin Mary Jane Brand. Cannabis Sativa was founded on November 5, 2005 and is headquartered in Mesquite, NV.

How useful was this post?

Click on a star to rate it!

Average rating 3 / 5. Vote count: 1

No votes so far! Be the first to rate this post.